Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Genetic Technologies ( (AU:GTG) ) has shared an announcement.
Genetic Technologies Limited has announced an agreement to sell its Direct-to-Consumer businesses and assets, including brands such as EasyDNA and AffinityDNA, as well as related intellectual properties and supply chain contracts. This strategic move aligns with the company’s restructuring efforts under administration and may influence its market focus on core molecular diagnostics, potentially impacting stakeholders by refining its operational focus and industry positioning.
More about Genetic Technologies
Genetic Technologies Limited is a diversified molecular diagnostics company, recognized globally for its genomics-based tests in health, wellness, and serious diseases through brands like geneType™ and EasyDNA. The company offers cancer predictive testing and risk assessment tools, and has developed a proprietary risk stratification platform integrating clinical and genetic risk for actionable health outcomes. It is a leader in risk prediction for oncology, cardiovascular, and metabolic diseases.
Average Trading Volume: 100
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.85M
See more insights into GTG stock on TipRanks’ Stock Analysis page.
